Phase 1 N=600 MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Solid Tumors
Primary: Dose-escalation: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 3; 3; 4; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=87 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Advanced Malignancies · Metastatic Cancer
Primary: Number of Participants With Treatment-related Adverse Events — 4; 4; 21; 17 Participants
Phase 2 N=28 A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Safety of NKTR-214 as Evaluated by Incidence of Drug-related Adverse Events (AEs) — 2; 8; 2; 1 events
Phase 1 N=110 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Neoplasms
Primary: Phase Ia Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs) in the First Cycle (3 Weeks) — 0; 0; 0 Participants
Phase 1 N=120 Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Endometrial Adenocarcinomas · Neuroendocrine Tumors · Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
Primary: Maximum Tolerated Dose (MTD) — 50; 50; 5.0; 5.0 DOX mg/m2 PM01183 mg FD
Phase 1 N=94 A Phase 1 Study of LY2874455 in Participants With Advanced Cancer
Advanced Cancer
Primary: Recommended Dose for Phase 2 Studies : Maximum Tolerated Dose (MTD) — 16 mg
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 1 N=50 Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
Melanoma · Metastatic Melanoma · Solid Tumor
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths — 4; 3; 3; 3 Participants
Phase 2 N=100 A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
Advanced Malignancies · Metastatic Cancer
Primary: Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) and as Per the Severity — 4; 4; 4; 3 Participants
Phase 1 N=29 Dose Finding Study of BI 836880 in Patients With Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 720 Milligram
Phase 1 N=147 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Part 1 · MELANOMA · SCCHN
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1 — 0; 0; 0; 0 Percentage of Participants
Phase 1 N=24 Weekly BI 836880 in Patients With Advanced Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)
Phase 1 N=198 Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
Advanced Solid Malignancies
Primary: Dose Escalation Phase: Maximum Tolerated Dose (MTD) — 6; 40; 9; 7 milligrams (mg)
Phase 1 N=104 Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)
Locally Advanced Tumors · Metastatic Solid Tumors · Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0; 0 Participants
Phase 1 N=72 A Trial In Patients With Advanced Cancer And Leukemia
Neoplasms by Histologic Type
Primary: Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT) — 0; 0; 0; 1 participants
Phase 1 N=191 Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Solid Tumor
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 59; 20; 21; 21 Participants
Phase 1 N=43 A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 4; 3; 13; 3 Participants
Phase 1 N=24 A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 1; 0; 0; 0 Participants
Phase 1 N=44 Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Advanced Solid Tumors
Primary: Objective Response Rate and Duration — 0; 0; 0; 0 participants with objective response
Phase 1 N=69 Monotherapy Dose Finding With BI 847325 in Solid Tumours
Neoplasms
Primary: Percentage of Patients With Dose Limiting Toxicity During the First Treatment Cycle in Phase Ia Part of the Study — 0; 0; 0; 0 Percentage of participants
Phase 1 N=25 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of MEDI0639 — NA milligram (mg)
Phase 1 N=35 A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
Cancer
Primary: Number of Participants With Adverse Events — 3; 3; 5; 3 Participants
Phase 2 N=176 Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
Cancer
Primary: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability — 24; 83; 33; 18 participants
Phase 1 N=110 A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Gastrointestinal Neoplasms · Cholangiocarcinoma · Pancreatic Neoplasms
Primary: Maximum Tolerated Dose (MTD) of BI 905711 in Phase 1a — NA milligram / kilogram (mg/kg)
Phase 2 N=106 Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Solid Tumors · Lymphomas
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAE) — 3; 3; 3; 3 participants
Phase 1 N=63 A Dose-Escalation Study for Patients With Advanced Cancer
Advanced Cancer
Primary: Recommended Dose and Schedule for Phase 2 Studies — 8 mg/m^2/day
Phase 1 N=114 MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
Solid Tumors
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1 Participants
Phase 1 N=19 Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) of CPX-POM — 0; 0; 0; 0 participants
Phase 1 N=35 Notch Inhibitor in Advanced Cancer
Advanced Cancer
Primary: Number of Participants With Clinically Significant Effects — 0; 1; 0; 0 Participants
Phase 1 N=77 A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
Locally Advanced, Metastatic Solid Tumors
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 — 1; 2; 1; 1 Participants